Literature DB >> 20713021

Specific inhibition of a pathogenic receptor tyrosine kinase by its transmembrane domain.

Lijuan He1, Nadia Shobnam, Kalina Hristova.   

Abstract

The transmembrane (TM) domains of receptor tyrosine kinases (RTKs) are believed to be important players in RTK signal transduction. However, the degree of specificity and promiscuity of RTK TM domain lateral interactions in mammalian membranes has not been assessed in detail in the literature. A technique to probe the occurrence of interactions between TM domains and their biological significance is to evaluate the propensity for formation of heterodimers of a full-length RTK and its TM domain. Here we examine if the inhibition of two RTK pathogenic mutants, Neu/V664E and FGFR3/A391E, can be achieved by the TM domains of Neu, Neu/V664E, FGFR3 and FGFR3/A391E. We show that the TM domain of Neu/V664E specifically inhibits the phosphorylation of full-length Neu/V664E, while the wild-type Neu TM domain does not. In addition, Neu/V664E TM domain does not affect the phosphorylation levels of full-length FGFR3/A391E. The results suggest that TM domain peptides could be exploited in the future for the development of specific inhibitors of mutant RTKs.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713021      PMCID: PMC2994959          DOI: 10.1016/j.bbamem.2010.08.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  47 in total

1.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.

Authors:  D B Weiner; J Liu; J A Cohen; W V Williams; M I Greene
Journal:  Nature       Date:  1989-05-18       Impact factor: 49.962

2.  Substitution of the erbB-2 oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin and insulin-receptor substrate 1.

Authors:  B Cheatham; S E Shoelson; K Yamada; E Goncalves; C R Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

Review 3.  A sequence motif in the transmembrane region of growth factor receptors with tyrosine kinase activity mediates dimerization.

Authors:  M J Sternberg; W J Gullick
Journal:  Protein Eng       Date:  1990-03

4.  High-yield trapping of EGF-induced receptor dimers by chemical cross-linking.

Authors:  B O Fanger; J E Stephens; J V Staros
Journal:  FASEB J       Date:  1989-01       Impact factor: 5.191

5.  Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.

Authors:  F J Lofts; H C Hurst; M J Sternberg; W J Gullick
Journal:  Oncogene       Date:  1993-10       Impact factor: 9.867

Review 6.  Specificity and promiscuity in membrane helix interactions.

Authors:  M A Lemmon; D M Engelman
Journal:  Q Rev Biophys       Date:  1994-05       Impact factor: 5.318

7.  Structural analysis of the transmembrane domain of the epidermal growth factor receptor.

Authors:  C D Carpenter; H A Ingraham; C Cochet; G M Walton; C S Lazar; J M Sowadski; M G Rosenfeld; G N Gill
Journal:  J Biol Chem       Date:  1991-03-25       Impact factor: 5.157

8.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.

Authors:  Y Kokai; J N Myers; T Wada; V I Brown; C M LeVea; J G Davis; K Dobashi; M I Greene
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

Review 9.  The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans.

Authors:  Z Vajo; C A Francomano; D J Wilkin
Journal:  Endocr Rev       Date:  2000-02       Impact factor: 19.871

10.  Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion.

Authors:  C I Bargmann; R A Weinberg
Journal:  EMBO J       Date:  1988-07       Impact factor: 11.598

View more
  13 in total

Review 1.  Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases.

Authors:  Kenneth Verstraete; Savvas N Savvides
Journal:  Nat Rev Cancer       Date:  2012-10-18       Impact factor: 60.716

2.  Strong dimerization of wild-type ErbB2/Neu transmembrane domain and the oncogenic Val664Glu mutant in mammalian plasma membranes.

Authors:  Jesse Placone; Lijuan He; Nuala Del Piccolo; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2014-03-11

Review 3.  Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them.

Authors:  Justin M Westerfield; Francisco N Barrera
Journal:  J Biol Chem       Date:  2019-12-25       Impact factor: 5.157

4.  High-throughput selection of transmembrane sequences that enhance receptor tyrosine kinase activation.

Authors:  Lijuan He; Andrew R Hoffmann; Christopher Serrano; Kalina Hristova; William C Wimley
Journal:  J Mol Biol       Date:  2011-07-12       Impact factor: 5.469

Review 5.  Transmembrane helix dimerization: beyond the search for sequence motifs.

Authors:  Edwin Li; William C Wimley; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2011-09-01

6.  Hydrophobic matching controls the tilt and stability of the dimeric platelet-derived growth factor receptor (PDGFR) β transmembrane segment.

Authors:  Claudia Muhle-Goll; Silke Hoffmann; Sergii Afonin; Stephan L Grage; Anton A Polyansky; Dirk Windisch; Marcel Zeitler; Jochen Bürck; Anne S Ulrich
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

7.  FGFR3 transmembrane domain interactions persist in the presence of its extracellular domain.

Authors:  Sarvenaz Sarabipour; Kalina Hristova
Journal:  Biophys J       Date:  2013-07-02       Impact factor: 4.033

Review 8.  Physical-chemical principles underlying RTK activation, and their implications for human disease.

Authors:  Lijuan He; Kalina Hristova
Journal:  Biochim Biophys Acta       Date:  2011-08-05

9.  Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3.

Authors:  Fenghao Chen; Sarvenaz Sarabipour; Kalina Hristova
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

10.  Neutralization of pro-inflammatory monocytes by targeting TLR2 dimerization ameliorates colitis.

Authors:  Liraz Shmuel-Galia; Tegest Aychek; Avner Fink; Ziv Porat; Batya Zarmi; Biana Bernshtein; Ori Brenner; Steffen Jung; Yechiel Shai
Journal:  EMBO J       Date:  2016-02-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.